Merck & Co., Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $65.0 | $64.2 | $60.1 | $59.3 | $48.7 |
| Net income | $18.3 | $17.1 | $0.4 | $14.5 | $13.0 |
| Balance Sheet | |||||
| Total debt | $49.3 | $37.1 | $35.1 | $30.7 | $33.1 |
| Cash Flow Statement | |||||
| Free cash flow | $12.4 | $18.1 | $9.1 | $14.7 | $8.7 |
| Dividends | $8.2 | $7.8 | $7.4 | $7.0 | $6.6 |
| Share repurchases | $5.1 | $1.3 | $1.3 | $0.0 | $0.8 |
Shares outstanding 2.5B · Free float 100.0%
Annual filing data through FY ended December 31, 2025; float as of September 19, 2026.
Earnings
Other Coverage
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
September 23, 2026
Drug Pipeline
Abivax, Merck and Teva–Sanofi pursue the next wave of colitis therapies
September 23, 2026
Drug Pipeline
Merck’s tulisokibart meets a Phase 3 ulcerative-colitis endpoint
August 14, 2026
Industry Earnings Roundup
Healthcare Earnings: Demand Surges, Costs Bite Back
July 4, 2026
Guidance Season
Chipmakers Lead a Guidance Season Almost Free of Cuts